NKGen Biotech, Inc., a clinical-stage biotechnology company focused on developing and commercializing innovative natural killer (NK) cell therapies, today announced the closing of its previously announced business combination with Graf Acquisition Corp. IV (GRAF).
This transaction resulted in NKGen becoming a publicly traded company on the Nasdaq Global Market under the “NKGN.”
NKGen’s NK cell therapies are designed to harness the power of the body’s immune system to fight cancer and other diseases. NK cells are a type of white blood cell that play a critical role in innate immunity, the body’s first line of defense against infection.
NKGen’s lead NK cell therapy candidate, SNK02, is an allogeneic NK cell therapy currently being evaluated in a Phase I clinical trial to treat solid tumors. NKGen is also developing autologous NK cell therapies for treating neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease.
The closing of this business combination provides NKGen with the financial resources and public market visibility necessary to accelerate the development and commercialization of its NK cell therapies.
“We are excited to complete this business combination and become a publicly traded company,” said Paul Y. Song, M.D., CEO of NKGen. “This transaction will allow us to expand our clinical programs, accelerate our manufacturing capabilities, and build a world-class team to bring our NK cell therapies to needy patients.”
NKGen’s business combination with GRAF is a significant milestone for the company and the field of NK cell therapy. It represents a vote of confidence in NKGen’s innovative platform and its potential to transform cancer treatment and other diseases.
The leadership landscape is profoundly changing, influenced by technological advancements, shifting workforce expectations, and the need for adaptability in an unpredictable global environment.
In the fast-paced business world, corporate leaders often find themselves at the crossroads of risk and reward, where bold decisions …
Corporate leaders often navigate turbulent waters where failure is not just a possibility but an inevitable part of the journey …
Corporate leaders play a pivotal role in shaping organizational cultures that embrace diversity and foster inclusivity. How can these …
Corporate leaders occupy a unique vantage point in the business world, offering insights and guidance shaped by their …
Corporate leaders today stand at the nexus of unprecedented technological evolution, where digital transformation reshapes industries and redefines …
January 15, 2025: South Korea’s ongoing political crisis is causing significant volatility in Asian financial markets..
January 14, 2025: The European Union’s Digital Services Act (DSA) reshapes how B2B platforms operate across Europe.
The leadership landscape is profoundly changing, influenced by technological advancements, shifting workforce expectations, and the need for adaptability in an unpredictable global environment.
The EU Green Deal is accelerating corporate sustainability efforts across industries, prompting significant leadership and strategic priorities shifts.
Leave us a message
Subscribe
Fill the form our team will contact you
Advertise with us
Fill the form our team will contact you
